Invetx secures $60.5 million in Series B funding

Invetx, a U.S.-based developer of veterinary drugs, has built an integrated, discovery, development and manufacturing platform to create fully species-specific, optimized and half-life-extended product candidates by leveraging proven biotechnologies from human health and optimizing them for use For veterinary medicine, the company can generate differentiated antibodies to treat a variety of chronic and serious diseases in animals. j recently raised $60.5 million in Series B funding. The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.